Analysis of Expression and Prognosis of KLK7 in Ovarian Cancer

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2020 Dec 18

PMID 33336051

Citations 1

Authors

Erhua Chen

Huifang Zhu

Yue Yang

Ling Wang

Jianhua Zhang

Yonghong Han

Xiang Liu

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer is one of the common malignant tumors in female reproductive organs. Kallikrein-related peptidase (KLK) 7 is a secreted serine peptidase that is related to different cancer. To investigate the expression and significance of KLK7 in ovarian cancer.

Materials And Methods: The expression of KLK7 in human ovarian cancer was evaluated by Oncomine and Cancer Cell Line Encyclopedia database. Then the co-expression genes relevant to the gene were analyzed by the Pearson correlation test. Finally, the impact of KLK7 on clinical prognosis was investigated in distinct subtypes of ovarian cancer patients by UALCAN database and Kaplan-Meier plotter database.

Results: It was found that the expression of KLK7 was higher in ovarian cancer compared with other types of cancer, such as gastric cancer and pancreatic cancer. The expression of KLK7 was found to be increased in four various ovarian cancer data sets compared with the healthy tissues. In addition, upregulation of KLK7 expression was associated with age and cancer stage. Moreover, survival analysis revealed that higher KLK7 expression was negatively associated with progression-free survival.

Conclusion: Knowledge of the expression of KLK7 may be useful for better understanding the outcome in ovarian cancer patients.

Citing Articles

KLK7, KLK10, and KLK11 in Papillary Thyroid Cancer: Bioinformatic Analysis and Experimental Validation.

Ni T, Zhao R, Wu J, Li C, Xue G, Lin X Biochem Genet. 2024; 62(6):4446-4471.

PMID: 38316654 DOI: 10.1007/s10528-024-10679-8.

References

Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R . Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014; 7:109. PMC: 4271347. DOI: 10.1186/s13048-014-0109-z. View

Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Diamandis E . Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann Oncol. 2008; 19(7):1271-1277. DOI: 10.1093/annonc/mdn035. View

Girgis A, Bui A, White N, Yousef G . Integrated genomic characterization of the kallikrein gene locus in cancer. Anticancer Res. 2012; 32(3):957-63. View

Suh-Burgmann E, Alavi M . Detection of early stage ovarian cancer in a large community cohort. Cancer Med. 2019; 8(16):7133-7140. PMC: 6853807. DOI: 10.1002/cam4.2522. View

Dong Y, Tan O, Loessner D, Stephens C, Walpole C, Boyle G . Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res. 2010; 70(7):2624-33. DOI: 10.1158/0008-5472.CAN-09-3415. View

Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H . Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009; 100(8):1421-8. PMC: 11159497. DOI: 10.1111/j.1349-7006.2009.01204.x. View

Silva L, Kryza T, Stoll T, Hoogland C, Dong Y, Stephens C . Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome. Mol Cell Proteomics. 2019; 18(5):818-836. PMC: 6495248. DOI: 10.1074/mcp.RA118.001304. View

Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements J . Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res. 2003; 9(5):1710-20. View

Hansson L, Stromqvist M, Backman A, Wallbrandt P, Carlstein A, Egelrud T . Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem. 1994; 269(30):19420-6. View

10.

Reyes I, Reyes N, Suriano R, Iacob C, Suslina N, Policastro A . Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma. Cancer Biomark. 2019; 24(1):71-83. DOI: 10.3233/CBM-181758. View

11.

Loessner D, Goettig P, Preis S, Felber J, Bronger H, Clements J . Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Expert Opin Ther Targets. 2018; 22(9):745-763. DOI: 10.1080/14728222.2018.1512587. View

12.

Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K . Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol Chem. 2013; 395(1):95-107. DOI: 10.1515/hsz-2013-0172. View

13.

Ejaz S, Nasim F, Ashraf M, Ahmad G . Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients. Heliyon. 2017; 3(7):e00356. PMC: 5522378. DOI: 10.1016/j.heliyon.2017.e00356. View

14.

Zheng S, Feng M, Yang G, Xiong G, Zheng L, Zhang T . [The expression of KLK7 in pancreatic cancer and the effects on the biological behavior of pancreatic cancer cells]. Zhonghua Wai Ke Za Zhi. 2018; 56(5):391-397. DOI: 10.3760/cma.j.issn.0529-5815.2018.05.013. View

15.

Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M . Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. Br J Cancer. 2018; 119(7):1-9. PMC: 6189062. DOI: 10.1038/s41416-018-0260-1. View

16.

Lu K, Patterson A, Wang L, Marquez R, Atkinson E, Baggerly K . Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004; 10(10):3291-300. DOI: 10.1158/1078-0432.CCR-03-0409. View

17.

Kyriakopoulou L, Yousef G, Scorilas A, Katsaros D, Massobrio M, Fracchioli S . Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003; 36(2):135-43. DOI: 10.1016/s0009-9120(02)00446-0. View

18.

La Vecchia C . Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev. 2016; 26(1):55-62. DOI: 10.1097/CEJ.0000000000000217. View

19.

McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334(1):1-6. DOI: 10.1056/NEJM199601043340101. View

20.

Pal P, Hales K, Petrik J, Hales D . Pro-apoptotic and anti-angiogenic actions of 2-methoxyestradiol and docosahexaenoic acid, the biologically derived active compounds from flaxseed diet, in preventing ovarian cancer. J Ovarian Res. 2019; 12(1):49. PMC: 6535187. DOI: 10.1186/s13048-019-0523-3. View